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Juvenile myelomonocytic leukemia (JMML) is classifiedas a combined myeloproliferative/ myelodysplastic dis-ease by the World Health Organization and accounts
for less than 3% of all childhood hematologic malignan-
cies.1,2 Children typically present at young age (median age
at diagnosis: two years) with hepatosplenomegaly, mono-
cytosis, anemia, thrombocytopenia and elevated HbF
(Figure 1).3,4 Morphology of the peripheral blood smear is
important for the diagnosis, and shows low blast percent-
ages and myeloid precursors. A bone marrow aspiration is
necessary to exclude acute myelomonocytic leukemia,
AML M4. In JMML, absence of the Philadelphia chromo-
some (BCR/ABL fusion gene) is one of the mandatory
diagnostic criteria.3,4 Cytogenetic analysis reveals mono-
somy 7 in 25% of the cases, random aberrations in the
karyotype in 10%, whereas in 65% of the cases a normal
karyotype is found.5 Figure 1 shows the currently used
diagnostic criteria.3,4
Molecular aberrations
RAS signaling pathway
In vitro GM-CSF hypersensitivity has been a hallmark of
JMML for the past two decades.6 This GM-CSF hypersen-
sitivity results from continuous activation of the GM-CSF-
receptor-RAS-RAF-MEK-ERK signal transduction path-
way. Currently, molecular aberrations, which will be dis-
cussed below, have become more important than the
hypersensitivity assay for diagnostic classification (Figure
1).3,4
Proteins encoded by the genes of the RAS family play a
role in the transduction of extracellular signals to the
nucleus and control proliferation and differentiation of
many cell types (Figure 2). RAS proteins are signaling mol-
ecules, which regulate cellular processes by switching
between an active [guanosine triphosphate (GTP) bound
RAS] and inactive [guanosine diphosphate (GDP) RAS]
form. The active GTP RAS activates the RAF kinase,
resulting in a downstream proliferative effect. The
amount of GTP-RAS is regulated by guanine nucleotide
exchange factors (GNEFs), and GTPase activating proteins
(GAPs). GNEFs are necessary for the conversion of GDP-
RAS into GTP-RAS and can be stimulated by upstream
proteins like Shp1 and Son of Sevenless (SOS). GAPs, like
neurofibromin, are responsible for the termination of the
RAS signaling by RAS-GTP conversion in RAS-GDP.7
Somatic mutations in this pathway are frequently found
in JMML, are mutually exclusive and result in continuous
activation and cell proliferation. Analysis of genetic syn-
dromes related to germline aberrations of the RAS path-
way, like neurofibromatosis type I and Noonan syndrome,
have increased the knowledge of the pathogenesis of
JMML. In reverse, the discovery of somatic JMML related
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Figure 1. Diagnostic criteria of juvenile
myelomonocytic leukemia.
PB: peripheral blood; BM: bone marrow; NF1: neurofibromatosis type 1;WBC: white blood cell count; HbF: fetal hemoglobin; GM-CSF: granulocyte macrophage- colony stimulat-
ing factor; * Splenomegaly is present at first presentation in 95% of cases.The majority of the patients are under than 13 years of age.
MANDATORY
• Peripheral blood monocyte count >1x109/L
• Blasts in PB/BM <20%
• Splenomegaly*
• Absence of BCR/ABL fusion gene
ONCOGENETICS
• Somatic mutation in RAS, PTPN11, NF1, or c-CBL
• Clinical diagnosis of NF1
• Monosomy 7
(One parameter sufficient)
IF NO ONCOGENETIC ABERRATION
• Circulating myeloid precursors
• WBC > 10x109/L
• Increased HbF for age
• Clonal abnormality besides monosomy 7
• Spontaneous growth or GM-CSF hypersensitivity in
clonal assay
(2 parameters have to be fulfilled)
 
RAS-pathway aberrations has resulted in the discovery of
germline RAS-pathway related mutations in Noonan like
syndromes such as Leopard syndrome, Costello syndrome
and Cardio-Facio-Cutaneous syndrome.8,9
NF1 mutations and clinical signs of neurofibromatosis type 1
Niemeyer et al. reported that 11% of the JMML patients
have clinical signs of neurofibromatosis type 1.5
Thereafter, Side et al. found NF1 gene mutations in 15% of
the JMML patients without clinical signs of NF1 (Figure
2).10 The NF1 gene is a tumor suppressor gene encoding
for neurofibromin, and is a GTPase activating protein
hydrolysing GTP-RAS into GDP-RAS.10 JMML cells from
children with NF1 showed a reduced neurofibromin activ-
ity, resulting in elevated GTP-RAS expression.11 In 2007,
Flotho et al. described somatic loss of heterozygosity
(LOH) in 4 out of 5 JMML cases with NF1. In the leukemic
cells the wild-type NF1 gene was replaced by a second
copy of the NF1 mutant 17q arm, resulting from uni-
parental disomy.12 In the current issue of this journal,
Steinemann et al.13 describe bi-allelic NF1 gene inactivation
in all cases in a larger cohort of JMML patients with NF1.
Again, this was either caused by LOH (n=10), or by
somatic mutations of the NF1 gene (n=5). This indicates
that although NF1 predisposes for JMML and other
leukemias, second events are necessary to abolish the
complete function of the NF1 gene in the development of
malignancies. Recently, comparable bi-allelic mutations in
the NF1 gene were also found in non-syndromic AML and
T-ALL patients, which underscores the fact that bi-allelic
inactivation of the NF1 gene is an important mechanism
in hematologic malignancies, but also that it is not JMML-
specific.14
RAS gene mutations
Mutations in the RAS genes are found in 20-30% of all
human tumors. In 25% of all JMML, activating point
mutations are found in codon 12, 13 and 61 of NRAS and
KRAS resulting in a continuous activation of the RAS path-
way (Figure 2).15
PTPN11 mutations
PTPN11 is a gene encoding for the non-receptor protein
tyrosine phosphatase SHP-2. Mutations in the PTPN11
gene cause a gain of function of the SHP2 protein. This
results in activation of the GNEFs and in this way to a con-
tinuous activation of RAS. Tartaglia et al. observed somatic
mutations in exon 3 and 13 of the PTPN11 gene in 35% of
the JMML patients without Noonan syndrome (Figure 2).16
Germline mutations in the PTPN11 gene have been
described in 50% of the Noonan syndrome cases. These
mutations differ from the somatic mutations found in
JMML.17 Noonan syndrome is characterized by develop-
mental disorders, short stature, facial dysmorphia, skeletal
anomalies and heart defects. Children with Noonan syn-
drome are at increased risk for developing JMML.
However, in Noonan syndrome, JMML seems to behave
differently from sporadic JMML as it occurs at a very
young age (infancy) and tends to regress spontaneously.18-
20 Therefore, recognising Noonan syndrome in a JMML
patient is important in order to identify those patients
who might benefit from a watch and wait policy.17,18
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GNEF: guanine nucleotide
exchange factor; GAP: GTPase
activating proteins; In JMML
in 35% of the cases a
PTPN11 mutation, in 20-25%
of the cases a RAS mutation,
in 17% a c-CBL mutation is
found. In 10-25% of the cases,
clinical signs of NF1 or NF1
gene mutations are found.
Figure 2. RAS-RAF-MEK-ERK signaling pathway.
c-CBL mutations
Recently Loh et al. identified c-CBL mutations in 17% of
the JMML patients, lacking RAS, PTPN11 or NF1 abnor-
malities (Figure 2). c-CBL is an E3 ubiquitin ligase, respon-
sible for the intracellular transport and degradation of a
large number of tyrosine kinase receptors, but also has
important adaptor functions. One of the proteins regulat-
ed by c-CBL is Grb2. This adaptor molecule binds to c-
CBL and in this way binding of c-CBL to SOS is prevent-
ed. Mutations in c-CBL have been shown to result in a
continuous activation of RAS.21,22
Other genes of the RAS pathway
So up till now, in about 80-85% of the JMML cases a
somatic mutation in the RAS pathway is found, indicating
that hyperactivation of the RAS pathway plays a central
role in the pathogenesis of JMML. Therefore, other genes
involved in the RAS-RAF-MEK-ERK pathway have been
investigated. Analysis of SHC1, GRB2, GAB1, SOS1,
BRAF and MEK 1 and MEK 2 genes revealed no muta-
tions.23,24 We and others showed that, upstream, FLT3
mutations are rare and we found no constitutively activat-
ed FLT3.25, 26
JAK-STAT pathway
It has been suggested that JMML is the juvenile counter-
part of chronic myelomonocytic leukemia (CMML) which
mainly occurs in adults, as also in CMML GM-CSF hyper-
sensitivity is found. However, JAK2 mutations (V617F)
which are found in in 3-13% of all CMML cases are a very
rare event in JMML, underscoring the differences between
JMML and CMML.26,27 Using flow cytometry, Kotecha et
al. found hyperphosphorylation of pSTAT5 in response to
subsaturating concentrations of GM-CSF. This supports
the hypothesis that the JAK2-STAT5 pathway plays a col-
laborating role in the pathogenesis of JMML but that JAK-
STAT5 activation mainly seems to occur by upstream of
activation of the RAS in the aberrant response of JMML
cells to GM-CSF.21,27
PTEN
Although all above mentioned studies have shown the
role of hyperactivation of the RAS pathway in JMML,
only few data are available documenting the status of the
other components downstream of RAS, like P13K and
MAPK. One of the other regulators of the P13K pathway
is PTEN, a tumor suppressor gene which antagonizes the
function of P13K and subsequently of AKT, and which is
involved in cell growth, proliferation, apoptosis and differ-
entiation. Liu et al. found PTEN protein deficiency in 67%
of the JMML patients and hypothesized that this deficien-
cy might lead to insufficient negative growth signals to
counter the hyperactive RAS pathway.28
Epigenetics
It has been suggested that PTEN protein deficiency can
be caused by hypermethylation of the promoter region of
PTEN.28 Apart from hypermethylation of PTEN, it was
recently shown that other epigenetic changes might play a
role in the pathogenesis of JMML as illustrated by Furlan et
al. They reported the first JMML patient, also characterized
by monosomy 7, treated with a DNA hypomethylating
agent. The patient revealed an excellent clinical and molec-
ular-genetic response, as illustrated by the disappearance of
the monosomy 7 and hypomethylation of the promoter
region of the CALCA gene after treatment.29 In addition,
other JMML studies showed mild hypermethylation of
specific genes, like p15, p16 and RASSF1A.30,31 These stud-
ies are important as they may point towards new, less toxic
treatment approaches which are already available for use
in the near future for at least subsets of JMML patients.
Treatment and prognosis
To date, the only curative treatment option for JMML is
stem cell transplantation (SCT). Intensive chemotherapy
does not represent a curative strategy, and splenectomy
before transplantation has never been shown to be of
benefit.32 The median survival time without SCT is about
one year.5 In the treatment protocol of the European
Working Group on Childhood MDS (EWOG MDS), the 5-
year event free survival after transplantation was in the
50% range and the cumulative relapse rate was 35%, with
a therapy related mortality rate of 15%.32 Results of a
study performed by the Children’s Oncology Group
including a farnesyltransferase in the pre-transplantation
window are underway.33 So far, no further data on the
effect of treatment with RAS pathway inhibitors are avail-
able. As indicated above, hypomethylating agents may be
a promising treatment option for the future.
Stem cell transplantation in this relatively young age cat-
egory of children with JMML harbors the risk of serious
toxicity, not only during the procedure but also in later
life. Hence, there is a need for unravelling the biology of
JMML in order to identify potential drug targets. 
Conclusion
JMML is a rare hematologic malignancy in childhood.
Increased knowledge of the molecular background has
enhanced diagnostic classification, as in more than 80% of
the cases mutations in RAS pathway related genes can be
found. NF1 is one of the genes which plays an important
role in the pathogenesis of JMML. The paper of
Steinemann et al. in the current issue13 of Haematologica
underscores the fact that in NF1, for developing JMML, bi-
allelic inactivation is necessary by either mutations or
LOH as a second event to abolish the complete function of
the NF1 gene.
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In the lay press it is frequently stated that long haul airtravel causes venous thrombosis through dehydra-tion in the airplane, leading to hyperviscosity of the
blood, which in its turn favors thrombosis. The com-
mon advice that is given to prevent thrombosis after air
travel is, therefore, ‘to drink ample amounts of fluids’
(http://www.britishairways.com/travel/healthmed-
cond/public/en_gb#DVT). This concept of thick, slowly
flowing blood is apparently intuitively appealing as a
cause of thrombosis. It would also fit the classical triad of
Virchow, who postulated that thrombosis is due to the
occurrence of stasis, to disturbances of the composition
High hematocrit as a risk factor for venous thrombosis. Cause or innocent bystander? 
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